Physician profile
Patrick W Hisel
NPI 1144228578
$1,507.65
in general payments reported to CMS, 2019-2025
24 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.15 · 2021: $136 · 2023: $24.39 · 2024: $72.15 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $324.45 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $233.18 | 2021-2025 | |
| Lilly USA, LLC | $204.45 | 2025 | Kisunla, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $137.35 | 2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $90.45 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Stryker Corporation | $49.33 | 2025 | Mako |
| Amgen INC. | $48.85 | 2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $43.01 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $41.65 | 2025 | Proclaim, Freestyle Libre 3 |
| Medtronic, INC. | $33.98 | 2025 | Intellis Adaptivestim, Venaseal |
| Astellas Pharma US INC | $32.60 | 2025 | Veozah |
| Beta Bionics, INC. | $31.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sanofi-Aventis U.S. LLC | $30.50 | 2025 | |
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Nevro Corp. | $24.39 | 2023 | Senza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.07 | 2025 | |
| Antares Pharma, INC. | $19.00 | 2025 | Xyosted |
| Abbvie INC. | $17.80 | 2025 | |
| Recordati_rare_diseases_inc. | $17.39 | 2025 | Isturisa |
| Agios Pharmaceuticals, INC. | $16.56 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $15.97 | 2025 | Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2025 | Jardiance |
| Insulet Corporation | $14.30 | 2025 | Omnipod |
| Ibsa Pharma INC. | $14.09 | 2025 | Licart, Tirosint, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Hisel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.